These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38832436)

  • 1. Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia.
    Sari TT; Wahidiyat PA; Rahmartani LD; Iskandar SD; Putri IA
    J Pediatr Hematol Oncol; 2024 Aug; 46(6):e402-e405. PubMed ID: 38832436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ
    Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A; Gillard S; Spino M; Connelly J; Tricta F
    Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
    Tripathy I; Panja A; Dolai TK; Mallick AK
    Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
    Pinto VM; Balocco M; Quintino S; Bacigalupo L; Gianesin B; Rizzi M; Malagò R; De Franceschi L; Forni GL
    Am J Hematol; 2018 Oct; 93(10):E338-E340. PubMed ID: 30033633
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni GL; Kattamis A; Kuo KHM; Maggio A; Sheth S; Taher AT; Viprakasit V
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31035. PubMed ID: 38753107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
    Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
    Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Gomber S; Jain P; Sharma S; Narang M
    Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
    BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
    Olivieri NF; Sabouhanian A; Gallie BL
    PLoS One; 2019; 14(2):e0211942. PubMed ID: 30811439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrolithiasis in two patients on iron chelation therapy: A case report.
    Dillon H; Baker Z; Pena A; Wang Y; Syed H; Sparks S
    Transfus Apher Sci; 2023 Jun; 62(3):103702. PubMed ID: 37055329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.